JP2014526462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526462A5 JP2014526462A5 JP2014529643A JP2014529643A JP2014526462A5 JP 2014526462 A5 JP2014526462 A5 JP 2014526462A5 JP 2014529643 A JP2014529643 A JP 2014529643A JP 2014529643 A JP2014529643 A JP 2014529643A JP 2014526462 A5 JP2014526462 A5 JP 2014526462A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- oncoprotein
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 102000027450 oncoproteins Human genes 0.000 claims 14
- 108091008819 oncoproteins Proteins 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102100034133 Dual specificity protein phosphatase 23 Human genes 0.000 claims 3
- 101100500211 Homo sapiens DUSP23 gene Proteins 0.000 claims 3
- 101000830689 Homo sapiens Protein tyrosine phosphatase type IVA 3 Proteins 0.000 claims 3
- 101000835900 Homo sapiens Submaxillary gland androgen-regulated protein 3B Proteins 0.000 claims 3
- 102100024601 Protein tyrosine phosphatase type IVA 3 Human genes 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100024599 Protein tyrosine phosphatase type IVA 1 Human genes 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010057649 Endometrial sarcoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 claims 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 claims 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 claims 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 claims 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 claims 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 claims 1
- 101000610550 Homo sapiens Opiorphin prepropeptide Proteins 0.000 claims 1
- 101001002066 Homo sapiens Pleiotropic regulator 1 Proteins 0.000 claims 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 claims 1
- 101000830696 Homo sapiens Protein tyrosine phosphatase type IVA 1 Proteins 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 101150105104 Kras gene Proteins 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028729 Nasal cavity cancer Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101710138644 Protein tyrosine phosphatase type IVA 1 Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101150077555 Ret gene Proteins 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 108700025184 hepatitis B virus X Proteins 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004995 male reproductive system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002990 parathyroid gland Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000037968 sinus cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531290P | 2011-09-06 | 2011-09-06 | |
| US61/531,290 | 2011-09-06 | ||
| SG2012011581A SG193038A1 (en) | 2012-02-17 | 2012-02-17 | Polypeptide vaccine |
| SG201201158-1 | 2012-02-17 | ||
| SG2012046447 | 2012-06-21 | ||
| SG201204644-7 | 2012-06-21 | ||
| PCT/SG2012/000305 WO2013036201A1 (en) | 2011-09-06 | 2012-08-29 | Polypeptide vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017106379A Division JP6676584B2 (ja) | 2011-09-06 | 2017-05-30 | ポリペプチドワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526462A JP2014526462A (ja) | 2014-10-06 |
| JP2014526462A5 true JP2014526462A5 (https=) | 2015-08-27 |
| JP6153526B2 JP6153526B2 (ja) | 2017-06-28 |
Family
ID=54259018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529643A Active JP6153526B2 (ja) | 2011-09-06 | 2012-08-29 | ポリペプチドワクチン |
| JP2017106379A Active JP6676584B2 (ja) | 2011-09-06 | 2017-05-30 | ポリペプチドワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017106379A Active JP6676584B2 (ja) | 2011-09-06 | 2017-05-30 | ポリペプチドワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10258676B2 (https=) |
| EP (1) | EP2753345B1 (https=) |
| JP (2) | JP6153526B2 (https=) |
| CN (2) | CN108434440B (https=) |
| SG (2) | SG10201903119QA (https=) |
| WO (1) | WO2013036201A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011100468A2 (en) | 2010-02-10 | 2011-08-18 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US20140005119A1 (en) * | 2012-06-28 | 2014-01-02 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS |
| JP6158184B2 (ja) * | 2012-08-10 | 2017-07-05 | 株式会社グリーンペプタイド | 上皮成長因子受容体のｔ７９０ｍ点突然変異配列に由来する抗原ペプチド |
| US20170049870A1 (en) * | 2012-08-10 | 2017-02-23 | Kanagawa Prefectural Hospital Organization | Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point Mutation |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US10441643B2 (en) * | 2014-03-19 | 2019-10-15 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3119427B1 (en) | 2014-03-19 | 2018-12-26 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
| EP3166630A4 (en) * | 2014-07-07 | 2018-03-28 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| SG10201404895XA (en) * | 2014-08-13 | 2016-03-30 | Agency Science Tech & Res | Diagnosis |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| TW202523682A (zh) * | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| WO2017120576A1 (en) * | 2016-01-07 | 2017-07-13 | Duke University | Cancer vaccines and methods of delivery |
| US12220451B2 (en) * | 2016-02-04 | 2025-02-11 | Duke University | Cell-based vaccine compositions and methods of use |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| AU2019403393B2 (en) * | 2018-12-20 | 2026-04-16 | The University Of Chicago | Methods and compositions related to therapeutic peptides for cancer therapy |
| WO2020145222A1 (ja) * | 2019-01-07 | 2020-07-16 | 地方独立行政法人神奈川県立病院機構 | 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬 |
| JP7831937B2 (ja) | 2019-09-03 | 2026-03-17 | クリエイト・メディシンズ，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| EP4056197A4 (en) * | 2019-11-07 | 2023-09-06 | Shenzhen Gino Biotechnology Co., Ltd. | TUMOR-SPECIFIC POLYPEPTIDE SEQUENCE AND USE THEREOF |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN111072763A (zh) * | 2019-12-23 | 2020-04-28 | 维塔恩(广州)医药有限公司 | 肿瘤相关基因gnas突变相关抗原短肽及其应用 |
| CN111393509B (zh) * | 2020-03-30 | 2022-03-29 | 国家纳米科学中心 | 靶向特异性多肽及其应用 |
| CN111285935B (zh) * | 2020-05-13 | 2020-09-11 | 方达医药技术(上海)有限公司 | 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途 |
| EP4199947A4 (en) | 2020-08-18 | 2024-10-16 | Onchilles Pharma, Inc. | Modified porcine pancreatic elastase proteins |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| US20240287149A1 (en) * | 2021-05-14 | 2024-08-29 | Oslo University Hospital | Mutated gnas peptides |
| CN116139253B (zh) * | 2021-08-10 | 2025-04-22 | 昆明医科大学 | 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用 |
| WO2025146078A1 (en) * | 2024-01-04 | 2025-07-10 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech, Inc., South San Francisco, Calif. | Her2 extrazellulare domäne |
| HUT68510A (en) * | 1991-08-26 | 1995-06-28 | Cytel Corp | Process for producing hla-restricted hapatitis b virus ctl epitopes and pharmaceutical compositions containing them |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| AU712441B2 (en) * | 1994-12-14 | 1999-11-04 | Scripps Research Institute, The | In vivo activation of tumor-specific cytotoxic T cells |
| US6514942B1 (en) | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US7329410B1 (en) * | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
| AU2001243196A1 (en) | 2000-02-22 | 2001-09-03 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
| US7105642B2 (en) | 2001-08-03 | 2006-09-12 | Cell Signalling Technology, Inc. | Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof |
| US7655751B2 (en) | 2004-01-23 | 2010-02-02 | Green Peptide Co., Ltd. | Epidermal growth factor receptor-derived peptides |
| EP1874342B1 (en) * | 2005-04-26 | 2018-06-06 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
| BRPI0608768B1 (pt) * | 2005-05-09 | 2019-08-20 | Vaxon Biotech | Uso de um peptídio nativo para a produção de uma composição medicinal, processo para a obtenção in vitro de ctls com elevada avidez por um peptídio nativo e kit de vacinação |
| WO2007110098A1 (en) * | 2006-03-29 | 2007-10-04 | Institut National De La Sante Et De La Recherche Medicale | HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV |
| WO2008008311A1 (en) * | 2006-07-10 | 2008-01-17 | The Trustees Of The University Of Pennsylvania | Methods for administering tumor vaccines |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| JP2010530735A (ja) * | 2007-05-03 | 2010-09-16 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体 |
| JP2010535503A (ja) * | 2007-08-10 | 2010-11-25 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ（エー＊エスティーエーアール） | 癌の診断および治療のためのｖｈｚ |
| KR100995340B1 (ko) * | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 |
| JP5756014B2 (ja) * | 2008-08-08 | 2015-07-29 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） | がんの診断および治療のためのｖｈｚ |
| KR101689408B1 (ko) | 2008-10-17 | 2016-12-23 | 다나-파버 캔서 인스티튜트 인크. | 암의 저해제로서 ｍｕｃ-1 세포질 도메인 펩티드 |
| EP2506864B1 (en) * | 2009-11-30 | 2016-07-27 | Agency For Science, Technology And Research | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| JP2013545969A (ja) * | 2010-10-15 | 2013-12-26 | ユニヴェルシテ リブル ドゥ ブリュッセル | エストロゲン受容体αポリペプチド配列、並びにその診断および治療用途 |
| CN102675422B (zh) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | 抗乙型肝炎病毒x蛋白多肽药物 |
| CN102675423B (zh) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | 抗乙型肝炎病毒x蛋白多肽药物 |
| CN102675424B (zh) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | 抗乙型肝炎病毒x蛋白多肽药物 |
| EP2562205A1 (de) * | 2011-08-22 | 2013-02-27 | Rhein Chemie Rheinau GmbH | Neue Folien für Solarzellen |
| CN102357246B (zh) | 2011-11-02 | 2013-04-03 | 江苏省中医药研究院 | 一种egfr与her2联合多肽表位疫苗 |
-
2012
- 2012-08-29 JP JP2014529643A patent/JP6153526B2/ja active Active
- 2012-08-29 CN CN201810214453.2A patent/CN108434440B/zh active Active
- 2012-08-29 SG SG10201903119QA patent/SG10201903119QA/en unknown
- 2012-08-29 SG SG11201400432VA patent/SG11201400432VA/en unknown
- 2012-08-29 US US14/342,644 patent/US10258676B2/en active Active
- 2012-08-29 WO PCT/SG2012/000305 patent/WO2013036201A1/en not_active Ceased
- 2012-08-29 EP EP12830226.2A patent/EP2753345B1/en active Active
- 2012-08-29 CN CN201280054509.3A patent/CN103987396A/zh active Pending
-
2017
- 2017-05-30 JP JP2017106379A patent/JP6676584B2/ja active Active
-
2019
- 2019-03-19 US US16/358,400 patent/US20200101147A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526462A5 (https=) | ||
| HRP20200383T1 (hr) | Ciljana vezna sredstva protiv b7-h1 | |
| JP2010213710A5 (https=) | ||
| JP2020125349A5 (https=) | ||
| JP2018517752A5 (https=) | ||
| JP2020504716A5 (https=) | ||
| JP2018027952A5 (https=) | ||
| SG11201903144PA (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| JP2020508302A5 (https=) | ||
| JP2015509540A5 (https=) | ||
| RU2017145280A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| AU2015327824A1 (en) | Multivalent meditopes, meditope-binding antibodies and uses thereof | |
| JP2018536705A5 (https=) | ||
| JP2016500684A5 (https=) | ||
| RU2014142057A (ru) | Комплексная терапия | |
| RU2012151571A (ru) | Лекарственные препараты для лечения рака | |
| JP2022065159A5 (https=) | ||
| JP2019524851A5 (https=) | ||
| HRP20211652T1 (hr) | Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze | |
| JP2025118769A5 (https=) | ||
| RU2014141934A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями | |
| JP2014532751A5 (https=) | ||
| HRP20230659T1 (hr) | Sastavi i metode za osjetljivost na viruse | |
| JP2011524355A5 (https=) | ||
| JP2019522681A5 (https=) |